Theravance Biopharma Inc. (TBPH) Reaches New 52-Week High at $35.18
Theravance Biopharma Inc. (NASDAQ:TBPH) shares reached a new 52-week high on Tuesday . The stock traded as high as $35.18 and last traded at $34.82, with a volume of 99,597 shares. The stock had previously closed at $33.67.
TBPH has been the subject of several recent analyst reports. Leerink Swann restated a “buy” rating on shares of Theravance Biopharma in a research note on Saturday, June 4th. Guggenheim initiated coverage on Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 target price for the company. Zacks Investment Research upgraded Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Tuesday, July 12th. Bank of America Corp. downgraded Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Finally, Evercore ISI initiated coverage on Theravance Biopharma in a research report on Monday, August 29th. They set a “buy” rating and a $41.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Theravance Biopharma currently has a consensus rating of “Hold” and a consensus target price of $34.50.
The firm’s 50 day moving average is $28.83 and its 200-day moving average is $23.24. The company’s market cap is $1.70 billion.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. Theravance Biopharma had a negative return on equity of 70.79% and a negative net margin of 471.82%. Equities research analysts forecast that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current fiscal year.
In other news, EVP Bradford J. Shafer sold 49,122 shares of Theravance Biopharma stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $27.46, for a total value of $1,348,890.12. Following the sale, the executive vice president now directly owns 241,686 shares of the company’s stock, valued at $6,636,697.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brett K. Haumann sold 4,491 shares of Theravance Biopharma stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $27.99, for a total value of $125,703.09. Following the completion of the sale, the senior vice president now directly owns 188,293 shares in the company, valued at $5,270,321.07. The disclosure for this sale can be found here. 4.70% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of the company. Teacher Retirement System of Texas raised its stake in shares of Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,401 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 192 shares in the last quarter. Bellevue Group AG purchased a new stake in shares of Theravance Biopharma during the first quarter worth about $215,000. Paloma Partners Management Co purchased a new stake in shares of Theravance Biopharma during the second quarter worth about $255,000. Finally, OMERS ADMINISTRATION Corp raised its stake in shares of Theravance Biopharma by 21.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 13,828 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 2,419 shares in the last quarter. 69.89% of the stock is currently owned by hedge funds and other institutional investors.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.